Clinical Trials Browser

Not yet recruiting × Biliary Tract Neoplasms × surufatinib × Clear all

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms